A Phase II/III, Single-blind(Stage 1), Double-blinded(Stage 2), Randomized, Active-controlled, Dose-escalation(Stage 1), Non-inferiority(Stage 2) Study to Evaluate Immunogenicity and Safety of MG1111 in Healthy Children
Latest Information Update: 17 May 2021
At a glance
- Drugs MG 1111 (Primary) ; Varicella zoster virus vaccine live
- Indications Varicella zoster virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors GC Pharma
- 12 Feb 2021 Status has beedn changed to completed as per Results published in the Vaccine
- 12 Feb 2021 Primary endpoint has been met. (Proportion of subjects who achieved seroconversion), as per Results published in the Vaccine
- 12 Feb 2021 Results published in the Vaccine